No association between the serotonergic polymorphisms and incidence of nausea induced by fluvoxamine treatment

European Neuropsychopharmacology

Volumn 12, Issue 5, 2002, Pages 477-481

  Takahashi, Hitoshi ^a   Yoshida, Keizo ^a   Ito, Kenich ^a   Sato, Kazuhiro ^a   Kamata, Mitsuhiro ^a   Higuchi, Hisashi ^a   Shimizu, Tetsuo ^a   Ito, Kunihiko ^b   Inoue, Kazuyuki ^b   Tezuka, Takehiko ^b   Suzuki, Toshio ^b   Ohkubo, Tadashi ^c   Sugawara, Kazunobu ^c  

^a AKITA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b AKITA UNIVERSITY HOSPITAL   (Japan)

^c HIROSAKI UNIVERSITY HOSPITAL   (Japan)

Author keywords

Fluvoxamine; Nausea; Pharmacogenetics; Serotonin

Indexed keywords

FLUVOXAMINE; SEROTONIN TRANSPORTER; TRYPTOPHAN HYDROXYLASE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DEPRESSION; DRUG BLOOD LEVEL; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; INTRON; MAJOR CLINICAL STUDY; MALE; NAUSEA; PHARMACOGENETICS; PREDICTION; PRIORITY JOURNAL; RATING SCALE; SEROTONINERGIC SYSTEM; TREATMENT OUTCOME; VARIABLE NUMBER OF TANDEM REPEAT;

ADULT; AGED; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CARRIER PROTEINS; CHI-SQUARE DISTRIBUTION; DEPRESSIVE DISORDER, MAJOR; FEMALE; FLUVOXAMINE; GENE FREQUENCY; GENOTYPE; HUMANS; INTRONS; LINKAGE DISEQUILIBRIUM; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; MIDDLE AGED; MINISATELLITE REPEATS; NAUSEA; NERVE TISSUE PROTEINS; POLYMORPHISM, GENETIC; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; TRYPTOPHAN HYDROXYLASE;

EID: 0036788875     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-977X(02)00056-1     Document Type: Article

References (19)

1. Bailey J.E., Potokar J.P., Coupland N.J. The 5-HT3 antagonist ondansetron reduces gastrointestinal side effects induced by a specific serotonin re-uptake inhibitor in man. J. Psychopharmacol. 9:1995;137-141.
2. Bellivier F., Leboyer M., Courtet P., Buresi C., Beaufils B., Samolyk D., Allilaire J.F., Feingold J., Mallet J., Malafosse A. Association between the tryptophan hydroxylase gene and manic-depressive illness. Arch. Gen. Psychiatry. 55:1998;33-37.
3. Bergeron R., Blier P. Cisapride for the treatment of nausea produced by selective serotonin reuptake inhibitors. Am. J. Psychiatry. 151:1994;1084-1086.
4. Buchner, A., Faul, F., Erdfelder, E., 1996. G·Power: A priori, post-hoc, and compromise power analyses for the Macintosh (Version 2.1.1) [computer program]. University of Trier, Trier, Germany.
5. Furlong R.A., Ho L., Walsh C., Rubinsztein J.S., Jain S., Paykel E.S., Easton D.F., Rubinsztein D.C. Analysis and meta-analysis of two serotonin transporter gene polymorphisms in bipolar and unipolar affective disorders. Am. J. Med. Genet. 81:1998;58-63.
6. Gorman J.M., Kent J.M. SSRIs and SNRIs: broad spectrum of efficacy beyond major depression. J. Clin. Psychiatry. 60:(Suppl. 4):1999;33-38.
7. Hartter S., Wetzel H., Hammes E., Torkzadeh M., Hiemke C. Serum concentrations of fluvoxamine and clinical effects. A prospective open clinical trial. Pharmacopsychiatry. 31:1998;199-200.
8. Kasper S., Fuger J., Moller H.J. Comparative efficacy of antidepressants. Drugs. 43:(Suppl. 2):1992;11-23.
9. Kim D.K., Lim S.W., Lee S., Sohn S.E., Kim S., Hahn C.G., Carroll B.J. Serotonin transporter gene polymorphism and antidepressant response. Neuroreport. 11:2000;215-219.
10. Lingjaerde O., Ahlfors U.G., Bech P., Dencker S.J., Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr. Scand. 76:(Suppl. 334):1987;81-94.
11. Montgomery S.A., Åsberg M. A new depression scale designed to be sensitive to change. Br. J. Psychiatry. 134:1979;382-389.
12. Ogilvie A.D., Battersby S., Bubb V.J., Fink G., Harmar A.J., Goodwim G.M., Smith C.A. Polymorphism in serotonin transporter gene associated with susceptibility to major depression. Lancet. 347:1996;731-733.
13. Serretti A., Zanardi R., Rossini D., Cusin C., Lilli R., Smeraldi E. Influence of tryptophan hydroxylase and serotonin transporter genes on fluvoxamine antidepressant activity. Mol. Psychiatry. 6:2001;586-592.
14. Serretti A., Zanardi R., Cusin C., Rossini D., Lorenzi C., Smeraldi E. Tryptophan hydroxylase gene associated with paroxetine antidepressant activity. Eur. Neuropsychopharmacol. 11:2001;375-380.
15. Shimoyama, R., Ohkubo, T., Sugwara, K., Otani, K., Yoshida, K., Higuchi, H., Shimizu, T., 2001. Plasma level monitoring of fluvoxamine and fluvoamino acid in depression patients by new developed HPLC Method. Presented at the Collegium Internationale Neuro-Psychopharmacologicum Regional Meeting, Oct. 2-5, Hiroshima, Japan.
16. Spigset O. Adverse reactions of selective serotonin reuptake inhibitors: reports from a spontaneous reporting system. Drug Saf. 20:1999;277-287.
17. van den Berg S.J. Comparing SSRIs: from chemistry to clinical choice. Hum. Psychopharmacol. 10:(Suppl. 3):1995;199-209.
18. Wilde M.I., Plosker G.L., Benfield P. Fluvoxamine. An updated review of its pharmacology, and therapeutic use in depressive illness. Drugs. 46:1993;895-924.
19. Zanardi R., Benedetti F., Di Bella D., Catalano M., Smeraldi E. Efficacy of paroxetine in depression is influenced by a functional polymorphism within the promoter of the serotonin transporter gene. J. Clin. Psychopharmacol. 20:2000;105-107.